

lar dinucleotide in this organism (12). Limited sequence specificity may reflect either low precision of an enzyme or else specific recognition of a structural feature of DNA, such as local helical twist, curvature, or mechanical flexibility.

That sequences altered by RIP are typically methylated suggests that methylation itself may play an active role in the mutation process, but this need not be so. The *N. crassa* genome contains "constitutive" methylated sequences that appear to go through crosses unaltered. Thus, methylation alone is not sufficient to cause the frequent transition mutations characteristic of RIP. Conversely, once rendered methylated by RIP, a sequence need not stay duplicated to retain methylation. When the elements of an unlinked duplication, methylated by RIP, segregate to separate cells, the resulting solitary elements continue to be methylated (2). Persistent methylation is not simply a result of passive maintenance methylation (4). Thus, the point mutations resulting from RIP must themselves be responsible for rendering the sequence a good substrate for DNA methylation. This finding is a potentially important clue for solving the mystery of why certain sequences are methylated in eukaryotes.

#### REFERENCES AND NOTES

1. E. U. Selker, E. B. Cambareri, B. C. Jensen, K. R. Haack, *Cell* **51**, 741 (1987).
2. E. U. Selker and P. W. Garrett, *Proc. Natl. Acad. Sci. U.S.A.* **85**, 6870 (1988).
3. The linked duplication of the parental strain T-ES174-1 resulted from integration of pES174 into genomic DNA by general recombination between the homologous segments [referred to as "flank" in (1) and (13)] of the plasmid and recipient cell. The second generation isolate used in this study, G<sub>2(T-1)</sub>:20-5, is abbreviated L-G<sub>2</sub> for linked second generation. The unlinked duplication of the parental strain T-ES174-9 resulted by nonhomologous integration of a single copy of the same plasmid. The first generation isolate G<sub>1(T-9)</sub>:3 is abbreviated U-G<sub>1</sub> for unlinked first generation.
4. E. B. Cambareri, M. J. Singer, E. U. Selker, unpublished results.
5. Strain K802; E. A. Raleigh and G. Wilson, *Proc. Natl. Acad. Sci. U.S.A.* **83**, 9070 (1986).
6. Homoduplexes of both plasmids were stable in spreading solutions containing as much as 80% formamide. Above this concentration, regions of pEC24 began to melt. The melting temperature of DNA is reduced by ~0.7°C for each 1% increase in formamide, and by essentially the same amount for each 1% increase in mismatch [see R. W. Davis and R. W. Hyman, *J. Mol. Biol.* **62**, 287 (1971)]. If we assume that the bubbles observed in pEC24/pEC25 hybrids at 40% formamide reflect sequence divergence, the sequences must have diverged at least ~40% in these regions.
7. J. Marmur and P. Doty, *J. Mol. Biol.* **2**, 109 (1962).
8. D. K. Butler and R. L. Metzberg, *Genetics*, in press.
9. B. K. Duncan and J. H. Miller, *Nature* **287**, 560 (1980).
10. C. Coulondre, J. H. Miller, P. J. Farabaugh, W. Gilbert, *Nature* **274**, 755 (1978).
11. D. Simon *et al.*, *ibid.* **304**, 275 (1983).
12. E. U. Selker and J. N. Stevens, *Proc. Natl. Acad. Sci. U.S.A.* **82**, 8114 (1985).
13. E. U. Selker, B. C. Jensen, G. A. Richardson, *Science* **238**, 48 (1987).
14. R. W. Davis, D. Botstein, J. R. Roth, *A Manual for Genetic Engineering: Advanced Bacterial Genetics* (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1980), pp. 188-191.
15. G. D. Fasman, Ed., *Handbook of Biochemistry and Molecular Biology*, vol. 2, *Nucleic Acids* (CRC Press, Cleveland, OH, ed. 3, 1976), p. 208.
16. We thank P. von Hippel and W. Rees for advice and assistance with the spectrophotometry, H. Foss for stimulating discussions, and L. Bruhn, H. Foss, D. Hawley, J. Selker, and W. Siström for comments on the manuscript. Supported by NIH grant GM 35690 and NSF grant DCB 8718163.

28 December 1988; accepted 6 April 1989

## Cloning of Breakpoints of a Chromosome Translocation Identifies the AN2 Locus


MANFRED GESSLER, KALLE O. J. SIMOLA, GAIL A. P. BRUNS

Chromosome translocations involving 11p13 have been associated with familial aniridia in two kindreds highlighting the chromosomal localization of the AN2 locus. This locus is also part of the WAGR complex (Wilms tumor, aniridia, genitourinary abnormalities, and mental retardation). In one kindred, the translocation is associated with a deletion, and probes for this region were used to identify and clone the breakpoints of the translocation in the second kindred. Comparison of phage restriction maps exclude the presence of any sizable deletion in this case. Sequences at the chromosome 11 breakpoint are conserved in multiple species, suggesting that the translocation falls within the AN2 gene.

THE PHENOTYPIC FEATURES OF THE WAGR syndrome (Wilms tumor, aniridia, genitourinary abnormalities, and mental retardation) indicate the presence of a constellation of genes important in human developmental processes within a small region of chromosome 11p13. Aniridia is a congenital developmental disorder of the eye, characterized by complete or partial absence of the iris, cataracts, lens anomalies, early onset glaucoma, and progressive loss of vision (1). It occurs in sporadic or autosomal dominant familial form without other phenotypic features at a frequency of 1:64,000 to 1:96,000. Many of the sporadic cases likely represent new mutations as aniridia is frequently inherited as an autosomal dominant in subsequent generations. Two genetic loci have been identified. In one large kindred, Ferrell *et al.* (2) observed linkage of aniridia (AN1) and the erythrocyte acid phosphatase (ACP1)

locus on chromosome 2p. The presence of a second aniridia locus, the AN2 locus, on chromosome 11p is supported both by the consistent association of aniridia with the constitutional 11p13 deletions of the WAGR syndrome (3) and by the different inherited translocations with 11p13 breakpoints associated with familial aniridia in two kindreds (4, 5). The breakpoints of both translocations were localized by somatic cell hybrid analysis between the genes encoding the beta subunit of follicle-stimulating hormone (FSHB) and catalase (CAT) within the critical region of overlap of WAGR deletions (6). Mapping and cloning of chromosomal translocation breakpoints has been a powerful tool for characterization of *myc*-

M. Gessler and G. A. P. Bruns, Genetics Division, The Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA 02115.  
K. O. J. Simola, Department of Medical Genetics, University of Helsinki, Helsinki, Finland.



**Fig. 1.** Long-range chromosomal map around the aniridia locus. The location of probes used in this study and cutting sites for the enzymes Not I (Nt), Nru I (Nr) and Sac II (Sc) were determined by pulsed-field gel analysis (12). The position of the breakpoints for the t(4;11) translocation (H.V.) and the approximate size of the deletion associated with the t(11;22) translocation (DG-85) are indicated. The centromeric breakpoint of t(11;22) is likely between the Not I site and 495 as a rearrangement of the adjacent Not I fragment was not detected by Compton *et al.* in the DG-85 cell line (16). Probe 495 is located on the centromeric and probe p495-3PH on the telomeric side of the H.V. translocation breakpoint.

related oncogenesis (7), the bcr region on chromosome 22 (8), and the Duchenne muscular dystrophy locus (9). Molecular analysis of the breakpoints of the two aniridia translocations would be expected to identify the gene and the nature of the translocation-related mutational events.

A cytogenetically undetected deletion involving two random chromosome 11p13 DNA probes was found to be associated with the translocation t(11;22)(p13;q12.2) in the cell line DG-85 by Davis *et al.* (10). Similarly, three probes (403, 495, and 582) from our panel of WAGR deletion probes are included in this deletion (11), which is postulated to encompass the aniridia gene or to disrupt its integrity leading to the aniridia phenotype in one kindred (5). To determine whether a similar deletion had occurred at the 11p13 breakpoint of the second aniridia translocation, DNA from H.V., an affected individual with the translocation t(4;11)(q23;p13), was analyzed for gene dosage with the three probes deleted in DG-85. No deletion of these or other adjacent probes could be detected.

To precisely locate the translocation breakpoint in H.V., we used the detailed long-range restriction map of the WAGR region that had been previously constructed

(12). In normal DNA, a series of probes (403, 495, 582, 570, and D11S16) recognize a 1.4-Mbp Not I fragment (Fig. 1). The telomeric end of this fragment is located approximately 0.5 Mbp centromeric to FSHB. In DG-85, altered Not I, Sac II, and Nru I fragments were seen with D11S16 and 570. A rearranged Not I fragment was also detected in H.V. DNA with these probes, suggesting that this translocation involves the same region. When probe 495 was used, however, the set of altered fragments in H.V. DNA differed from those seen with other more distal probes like 582 and D11S16, suggesting that 495 is centromeric to the breakpoint.


The breakpoint in H.V. was defined more exactly by using short-range pulsed-field gel electrophoresis (PFGE) to analyze the immediate surrounding of probes 495 and 582 (Fig. 2a). The enzymes Sac II, Sfi I, and Sal I, which produce fragments of 330 to 410 kbp with probe 495 in normal DNA, yielded additional altered fragments in H.V. DNA. The presence of a new 140-kbp Sal I fragment, derived from the der(11) chromosome, implied that the breakpoint had occurred within this limited area.

Probe 495 itself detected no rearrangement in H.V. DNA on conventional South-



ern blots with the enzymes Eco RI, Bam HI, Kpn I, and Hind III. However, a chromosome walking step from 495 led to the isolation of  $\lambda$ 495-3 (13). After preannealing with human placental DNA to remove repetitive sequences, the complete insert of  $\lambda$ 495-3 detected altered fragments for Eco RI, Bam HI, and Hind III in H.V. DNA. On PFGE blots, subclones p495-3ES and p495-3PH recognized the same normal fragments as 495, but the altered fragments were of different size (Fig. 2b). The detection of a completely different set of altered fragments indicated that the translocation breakpoint had been crossed. Probe p495-3ES was used to isolate a recombinant phage  $\lambda$ HV-1 (Fig. 3a), containing the 13-kb Bam HI fragment of the rearranged der(4) allele (13). Restriction maps for  $\lambda$ 495-3 and  $\lambda$ HV-1 were identical in the telomeric region and agreed with genomic restriction maps as verified by hybridization with probes p495-3ES and p495-3PH. A unique fragment derived from the centromeric region of  $\lambda$ HV-1 (pHV-Sac3) and not present in  $\lambda$ 495-3 was mapped to human chromosome 4 with a somatic cell hybrid panel (14), thereby confirming the identity of the breakpoint clone. The corresponding unrearranged chromosome 4 allele was isolated by screening a human Mbo I partial digest library with pHV-Sac3. A unique fragment, pCH4S-Eco, derived from  $\lambda$ CH4-1 correctly maps to chromosome 4 and is located distal to the chromosome 4 breakpoint. As the region between 495 and the chromosome 11 breakpoint is rich in repetitive sequences, the der(11) allele was isolated with probe pCH4S-Eco from a Bgl II digest library of H.V. DNA (13).

Comparison of restriction maps for the isolated phage clones showed no differences between rearranged alleles and their normal counterparts outside of the breakpoint region. The breakpoint was localized by restriction mapping within fragments of 250 and 350 bp on chromosome 11 and 4, respectively. There was no indication that the translocation resulted in a concomitant deletion, although loss of a few nucleotides could not be excluded by comparison of the restriction maps. The absence of a significant deletion is substantiated by the fact that p495-3AH, a 350-bp fragment that spans the translocation breakpoint on chromosome 11, detects the der(4) and the der(11) homologs in H.V. DNA (Fig. 3b).

The breakpoint probe p495-3AH and probe p495-3PH, located immediately distal to the breakpoint, hybridized with rodent sequences on the hybrid cell panels used to confirm their chromosome assignment. In fact, both probes identify cross-



**Fig. 2.** Detection of the t(4;11)(q22;p13) rearrangement by short-range PFGE. DNA from a normal lymphoblastoid cell line (N) and DNA from H.V. (T) were digested with the enzymes indicated and PFGE blots prepared as described (17). Probe 495 (A) detects additional fragments in H.V. DNA (\*), derived from the der(11) chromosome. With longer switching times, the altered Sac II fragment in H.V. DNA can be resolved and separated from the Sac II partial digest fragment of normal DNA. Probe p495-3PH (B) identifies the same normal fragments as probe 495; the altered fragments in H.V. DNA (◄), however, are different and are derived from the der(4) chromosome. Sizes on the right were obtained from *Saccharomyces cerevisiae* chromosomes. Electrophoresis conditions for the gel were 330 V, 11°C, 35-s switching time for 33 hours.



**Fig. 4.** Conservation of probe p495-3AH sequences. A Southern blot filter containing 4 μg of Hind III-digested DNA from human (1), chimpanzee (2), dog (3), hamster (4), and chicken (5) was hybridized with probe p495-3AH in 0.5M Na(PO<sub>4</sub>), pH 7.2, 1% SDS, 1 mM Na<sub>2</sub> EDTA, and salmon sperm DNA (50 μg/ml) at 65°C (18). The filter was washed for 1.5 hours in 40 mM Na(PO<sub>4</sub>), pH 7.2, 1% SDS at 65°C, and exposed overnight.

tions in the Finnish kindred, it represents the likely cause of the disorder. The translocation could disrupt the aniridia gene itself or alter regulatory elements for the gene in the affected individuals. Initial sequence analysis of the breakpoint region showed that the translocation occurred within an open reading frame that is flanked by consensus splice donor and acceptor sites, suggesting that it may represent an exon. An RNA transcript corresponding to the two conserved probes has not yet been detected on Northern blots. This may reflect a very narrow window of expression for this gene during development.

For Duchenne muscular dystrophy and

**Fig. 3.** Restriction maps of phage isolates for both rearranged and normal alleles of the t(4;11)(q22;p13) cell line and localization of the break-points. (A) Sites for the restriction enzymes Eco RI (E), Hind III (H), Bam HI (B), Bgl II (Bg), Acc I (A), Sac I (Sc), and Xba I (X) are indicated as determined from digests of phage DNA or plasmid subclones. For Bgl II, Acc I, and Xba I, only the sites in the vicinity of the breakpoint were mapped precisely. The localization of different plasmid subclones used in this study, representing the chromosome 11 (top) and chromosome 4 (bottom) alleles, is indicated by shaded boxes. (B) Probe p495-3AH spans the translocation breakpoint. Normal DNA (N) and DNA from H.V. (T) was digested with the enzymes shown. In H.V. DNA the rearranged fragments corresponding to the der(4) (▶) and the der(11) (\*) alleles are identified in addition to the normal fragments, which are seen in the control lane. Since the probe contains an internal Bam HI site, the region of homology with the rearranged der(11) fragment is likely too short to allow visualization of this small fragment [see (A)].

retinoblastoma, the isolation of sequences with extensive evolutionary conservation led directly to the cloning of the genes (15). The highly conserved probes at and adjacent to the t(4;11) translocation breakpoint should be similarly important for cloning of the aniridia gene and subsequent elucidation of how dominantly inherited mutations at this locus perturb developmental processes in the eye.

#### REFERENCES AND NOTES

1. L. B. Nelson *et al.*, *Surv. Ophthalmol.* **28**, 621 (1984).
2. R. E. Ferrell, A. Chakravarti, H. M. Hittner, V. M. Riccardi, *Proc. Natl. Acad. Sci. U.S.A.* **77**, 1580 (1980); R. E. Ferrell, A. Chakravarti, S. Antonarakis, J. H. Antoszyk, H. M. Hittner, *Cytogenet. Cell Genet.* **46**, 614 (1987).
3. U. Francke, L. B. Holmes, L. Atkins, V. M. Riccardi, *Cytogenet. Cell Genet.* **24**, 185 (1979); V. M. Riccardi *et al.*, *Cancer Genet. Cytogenet.* **2**, 131 (1980).
4. K. O. J. Simola, S. Knuutila, I. Kaitila, A. Pirkola, P. Pohja, *Hum. Genet.* **63**, 158 (1983).
5. J. W. Moore, S. Hyman, S. E. Antonarakis, E. H. Mules, G. H. Thomas, *ibid.* **72**, 297 (1986).
6. T. Glaser *et al.*, *Nature* **321**, 882 (1986); D. J. Porteous *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **84**, 5355 (1987).
7. R. Dalla-Favera *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **79**, 7824 (1982); R. Taub *et al.*, *ibid.*, p. 7837.
8. A. de Klein *et al.*, *Nature* **300**, 765 (1982); J. Groffen *et al.*, *Cell* **36**, 93 (1984).
9. S. E. Bodrug *et al.*, *Science* **237**, 1620 (1987).
10. L. M. Davis *et al.*, *ibid.* **241**, 840 (1988).
11. G. A. P. Bruns, S. D. Barnes, M. Gessler, J. B. Brennick, M. J. Weiner, *Cytogenet. Cell Genet.* **47**, 588 (1987); M. Gessler *et al.*, *Am. J. Hum. Genet.* **44**, 486 (1989).
12. M. Gessler, K. O. J. Simola, G. A. P. Bruns, *Am. J. Hum. Genet.* **43**, A183 (1988); M. Gessler and G. A. P. Bruns, *Genomics*, in press.
13. Phage clones λ495-3 and λCH4-1 were isolated by

hybridizing DNA sequences in a number of higher vertebrates at high stringency of hybridization (Fig. 4), suggesting that they may contain coding sequences. As the H.V. chromosome translocation cosegregates with the aniridia phenotype in three genera-

- standard protocols from an Mbo I partial digest human genomic library in EMBL3, provided by S. Orkin. Clone  $\lambda$ HV-1 was isolated from a complete Bam HI digest library of H.V. DNA in EMBL3 and packaged with Gigapack plus (Stratagene). The  $\lambda$ HBgl-1 clone was isolated from a Bgl II complete digest library of H.V. DNA in EMBL3 prepared without phosphatase treatment or size selection of the insert to ensure clonability of the 8-kbp rearranged fragment.
14. The segregation of pHV-Sac3 was completely concordant with that of chromosome 4 in 15 hybrids. Discordancy fractions for the other chromosomes ranged from 0.21 to 0.66.
  15. A. P. Monaco *et al.*, *Nature* **323**, 646 (1986); S. F. Friend *et al.*, *ibid.*, p. 643; Y.-K. T. Fung *et al.*, *Science* **236**, 1657 (1987); W.-H. Lee *et al.*, *ibid.* **235**, 1394 (1987).
  16. D. A. Compton *et al.*, *Cell* **55**, 827 (1988).
  17. M. Gessler and G. A. P. Bruns, *Genomics* **3**, 117 (1988).
  18. G. M. Church, and W. Gilbert, *Proc. Natl. Acad. Sci. U.S.A.* **81**, 1991 (1984).
  19. We thank G. Jaschek for technical assistance. Supported by NIH grant GM 34988. M.G. is recipient of a postdoctoral fellowship from the Deutsche Forschungsgemeinschaft through the University of Giessen, Federal Republic of Germany.

17 January 1989; accepted 28 April 1989

## The Molecular Basis of Muscular Dystrophy in the *mdx* Mouse: A Point Mutation

PIOTR SICINSKI,\* YAN GENG, ALLAN S. RYDER-COOK, ERIC A. BARNARD, MARK G. DARLISON, PENE J. BARNARD†

The *mdx* mouse is an X-linked myopathic mutant, an animal model for human Duchenne muscular dystrophy. In both mouse and man the mutations lie within the dystrophin gene, but the phenotypic differences of the disease in the two species confer much interest on the molecular basis of the *mdx* mutation. The complementary DNA for mouse dystrophin has been cloned, and the sequence has been used in the polymerase chain reaction to amplify normal and *mdx* dystrophin transcripts in the area of the *mdx* mutation. Sequence analysis of the amplification products showed that the *mdx* mouse has a single base substitution within an exon, which causes premature termination of the polypeptide chain.

THE *mdx* MOUSE WAS FIRST RECOGNIZED as a glycolytic X-linked mutant with myofiber necrosis and was proposed as a possible animal model for the X-linked human disease of dystrophin deficiency, Duchenne muscular dystrophy (DMD) (1). The absence of dystrophin (2) and reduced dystrophin RNA levels (3) later noted in the *mdx* mouse supported this concept, but the successful muscle fiber regeneration and reduced endomysial fibrosis (4) are in marked contrast to the DMD phenotype, casting doubt on its genetic homology (5). However, mapping of cDNA clones encoding the entire human DMD transcript showed that the *mdx* mutation is indeed located within the mouse dystrophin gene, which is the homologue of the human DMD locus (6). DMD has one of the highest mutation rates known (7), and more than 50% of affected males are known to have deletions (8).

To characterize the mutation in the inbred *mdx* mouse, we narrowed the limits of the mouse DNA sequence where the muta-


tion had been predicted to be by human dystrophin cDNA probes (6). An adult mouse muscle cDNA library, constructed in the vector  $\lambda$ gt10 with random primers, was screened with cloned cDNA sequences encoding human dystrophin to provide cDNA clones that encompassed almost the entire coding region of the mouse dystrophin transcript. Mouse clones spanning the known region of the *mdx* mutation were thus isolated and identified by DNA sequencing and by comparison with mouse (9) and human (10) dystrophin cDNA sequences (Fig. 1). These clones were used to probe Southern

blots of Taq I-digested genomic DNA from three animals that showed recombination within the mouse dystrophin gene in a large interspecific mouse pedigree that contained the *mdx* mutation (6). By this method, we were able to identify by recombination analysis an even smaller region in which the mutation must lie.

The recombinational breakpoint in the 5' end of the gene was found to lie between nucleotides 2083 and 3637 [numbers throughout correspond to those of the human cDNA sequence (10)] by using mouse clones MAD 18, MAD 19-2, and MAD 21 (Fig. 1). The breakpoint in the 3' end of the gene was found to lie between nucleotides 6400 and 6783 by using overlapping fragments derived from clones MAD 25, MAD 26, MAD 28, MAD 29, and MAD 36-1 (not shown). Thus, the *mdx* mutation must lie between nucleotides 2083 and 6783. There was no evidence of any difference between normal and *mdx* DNA on Southern blots with any of the probes spanning this region, which indicated that a large insertion or deletion was not present.

Because of the low steady-state amounts of dystrophin transcript in normal muscle (9) and the still lower levels in *mdx* muscle (3), the polymerase chain reaction (PCR) (11) was applied to normal and *mdx* cDNA to amplify the region of the mutation. This 4.7-kb interval was amplified in six overlapping steps. We designed synthetic oligonucleotides (24 to 30 bases in length) on the basis of the normal mouse sequence, and we used these with total RNA in first-strand cDNA synthesis and subsequent PCR amplification. DNA blot analysis of the entire 4.7-kb interval showed no obvious difference in the size of the amplification products of *mdx* and normal mouse RNA (Fig. 2). However, DNA sequence analysis of normal and *mdx* cDNAs revealed a single base substitution in *mdx* mice when compared to normal animals. In *mdx* mice, a cytosine is

**Fig. 1.** Map of mouse dystrophin cDNA clones. The positions of cloned mouse dystrophin cDNA sequences are indicated. The entire coding region shown was cloned from a single library. Total RNA was isolated from normal leg muscle from 14-week-old C57B1/10 mice with guanidinium isothiocyanate (19), and polyadenylated RNA



was selected (20). From this RNA, a size-selected random-primed cDNA library was constructed in  $\lambda$ gt10, originally comprising approximately  $2 \times 10^6$  independent recombinants. The library was plated and screened (21) with pCa1A (22) and with human cDNA probes 67, 73, 75, and 77 [which correspond to fragments 1a-2, 5b-7, 8, and 9-14, respectively (8)]. Between 3 and 20 positive clones were obtained from a screen of 500,000 unamplified recombinant phage. Inserts were subcloned into M13 vectors, sequenced by the dideoxy chain termination method (23), and positioned after comparison with the published sequences (9, 10).

Medical Research Council Molecular Neurobiology Unit, MRC Centre, Hills Road, Cambridge CB2 2QH, United Kingdom.

\*Present address: Department of Histology and Embryology, Medical Academy, Chalubinskiego 5, Warsaw, Poland.

†To whom correspondence should be addressed.